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http://dx.doi.org/10.1016/j.jmii.2013Background: Although echinocandins have high in vitro antifungal efficacy according to prior
reports, comparative studies on the clinical cure rates of anidulafungin, caspofungin, and mi-
cafungin in systemic candida infections have not yet been reported.
Methods: Interpretation of clinical and microbiological responses to anidulafungin, caspofun-
gin, and micafungin in 109 cases of candidemia was done according to the published criteria.
The clinical cure rates between patients treated with echinocandins and patients treated with
fluconazole were also compared. The minimal inhibitory concentrations (MICs) of anidulafun-
gin, caspofungin, micafungin, and fluconazole for these 109 blood isolates of candida were
determined with the Clinical and Laboratory Standards Institute M27-A reference microdilution
method. Logistic regression with forward selection was used to determine the important fac-
tors of prognosis with variables such as age, underlying diseases, acute physiology and chronic
health evaluation (APACHE) III score, persistent candidemia, and antimicrobial therapy.
Results: Among the 109 cases of candidemia, 70 were treated with echinocandins, azoles, or
amphotericin B for 7 days. The clinical cure rate of cases treated with antifungal agents
adequately (7 days) and inadequately (<7 days) were 44/70 (62.9%) and 4/39 (10.2%),nfectious Diseases, Chang Gung Memorial Hospital, 222 Mai Chin Road, Keelung, Taiwan.
t.net (S.-C. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
.09.006
246 S.-C. Lee et al.respectively, with significant difference (p < 0.0001). Clinical cure rates of anidulafungin, cas-
pofungin, micafungin, and fluconazole were 18/30 (60.0%), 8/9 (88.9%), 5/7 (71.4%), and 9/18
(50%), respectively. The difference in APACHE III score between treatment success and failure
cases was significant. The MIC50/MIC90 of anidulafungin, caspofungin, and micafungin for all
Candida spp. were 0.03/1 mg/mL, 0.06/0.5 mg/mL, and 0.008/1 mg/mL, respectively.
Conclusion: Adequate antifungal therapy and APACHE III score are both independent factors
affecting the clinical outcome. The clinical cure rate of the echinocandins group was higher
than that of the fluconazole group without significant difference. Although caspofungin had
the best clinical cure rate in this study, there was no significant difference between the clinical
cure rates among these three echinocandins. All Candida spp. were susceptible in vitro to
these three echinocandins.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Significant factors affecting the clinical outcome of candide-
mia and the associated mortality among critical patients in
medical intensive care units have been reported.1,2 Prior
studies indicate that echinocandins such as anidulafungin,
caspofungin, and micafungin manifest in vitro fungicidal ac-
tivity against candida.3e10 Furthermore, the clinical cure rate
of caspofungin has been compared with that of micafungin
and liposomal amphotericin B in invasive candida in-
fections.11,12 Anidulafungin has also been compared with flu-
conazole in the treatment of candidemia.9 Nonetheless, to
our knowledge, comparative studies on the clinical cure rates
of anidulafungin, caspofungin, and micafungin in systemic
candida infections has not yet been reported.10e17 Therefore,
this study sought to compare the clinical efficacy of these
three echinocandins, as well as their in vitro efficacy in pa-
tients of candidemia. The clinical cure rates betweenpatients
treated with echincandins and patients treated with flucon-
azole were compared. Associated risk factors for treatment
failure and mortality in candidemia were also investigated.
Methods
Patient enrollment
Keelung Chang Gung Memorial Hospital is a 1088-bed,
tertiary-care, teaching hospital in Taiwan. This research was
started in March 1, 2010 after being approved in February
2010. All candidemia patients in Keelung Chang Gung Me-
morial Hospital were enrolled between March 1, 2010 and
December 31, 2011 for retrospective clinical analysis. In-
clusion criteria were: (1) at least one blood culture positive
for Candida spp.; (2) pre-existing risk factors for invasive
Candida infection mentioned in literature2; and (3) clinical
manifestation of sepsis. The patients’ Candida isolates were
stored for in vitro susceptibility study.
Treatment regimens
All candidemia patients were treated with fluconazole or
echinocandins with approval from an infectious disease
specialist according to the Clinical Practice Guidelines forthe Management of Candidiasis by the Infectious Diseases
Society of America in 2009.18 In patients with serum
creatinine levels below 3 mg/dL, 200 mg of fluconazole was
administered intravenously twice daily after a loading dose
of 300 mg for 1e4 weeks (at least 1 week after blood
culture-negative), depending on the patients’ clinical
response.19 In patients with serum creatinine levels above
3 mg/dL, a 200 mg dose of fluconazole was administered
intravenously once daily.19 The loading dose of anidula-
fungin was 200 mg followed by a maintenance dose of
100 mg intravenously once daily for 1e4 weeks. The loading
dose of caspofungin was 70 mg followed by a maintenance
dose of 50 mg intravenously once daily for 1e4 weeks.9,10,20
In the case of micafungin, there was no loading dose and a
maintenance dose of 100 mg intravenously was given once
daily for 1e4 weeks.21 Coexisting bacterial infections were
treated with appropriate antibiotics according to the anti-
microbial susceptibility.19 Surgery was performed if neces-
sary to eradicate the infections upon obtaining informed
patient consent.19 Dosage of echinocandins including ani-
dulafungin, caspofungin, and micafungin remained un-
changed for patients with abnormal renal function.
Evaluation criteria
Follow-up evaluations were performed daily by the
attending physician in charge after the start of treatment.
Standard clinical laboratory evaluations (blood chemistry,
urinalysis, complete blood count, blood bacterial and
fungal culture, and chest roentgenogram) were performed
prior to, during, and after treatment as medically indi-
cated. Interpretation of the clinical and microbiological
responses was done according to the following criteria.19
Clinical cure was indicated by the resolution of clinical
signs and symptoms of infection due to the original Candida
species, without signs of infection relapse caused by the
original Candida species within 3 months after the discon-
tinuation of the antifungal agent and the absence of the
original Candida species in repeated post-therapy cul-
tures.19 Any coexisting bacterial infection was treated with
appropriate antibiotics as recommended by infectious dis-
eases specialists. Clinical treatment failure was indicated
by an absence of clinical response to antifungal therapy
after a minimum of 1 week of therapy, with persistence of
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Candidemia mortality risk, echinocandins efficacy 247positive culture or development of unacceptable drug
toxicity.19 Superinfection or reinfection due to Candida
species different from the original Candida species were
excluded prior to evaluation.19 Surgical intervention
essential to the eradication of infection was performed
prior to evaluation. Mortality due to candidemia was
defined as death of patients due to sepsis within 30 days of
the last detection of Candida-positive blood culture
without clinical response to antifungal therapy or with
persistence of positive culture after a minimum of 1 week
of therapy.19 Death of candidemia patients >30 days after
the last detection of candidemia after completing an
adequate course of antifungal therapy and with repeated
negative blood culture was defined as mortality due to
other causes.19 Early antifungal therapy was defined as an
antifungal therapy being started within 48 hours of positive
blood culture. Inadequate treatment was defined as
treatment with fluconazole and/or echinocandins for <7
days whereas adequate treatment was defined as treat-
ment with fluconazole and/or echinocandins for 7 days.
Persistent candidemia was diagnosed when repeated blood
culture still presented positive for the same Candida spp.
>24 hours after the first positive blood culture even under
antifungal therapy or after a completed course of anti-
fungal therapy. The relationship of the acute physiology
and chronic health evaluation (APACHE) III score to clinical
cure rate and mortality due to candidemia were also
evaluated on the blood culture-positive day.22
In vitro susceptibility test
MICs were determined and interpreted for the 109 Candida
isolates causing 109 candidemia episodes according to the
procedure of the current reference method for broth dilu-
tion antifungal susceptibility testing of yeasts (M27-A3 and
M27-S3) by the Clinical and Laboratory Standards Institute
(CLSI).23,24 Briefly, Candida isolates at a final concentration
of 5.0  105 cells/L to 2.5  106 cells/L were incubated in
air at 35C for 24 hours with two-fold dilutions of antifungal
agents of 0.03e16 mg/mL for amphotericin B; 0.125e64 mg/
mL for fluconazole; 0.008e16 ug/mL for itraconazole,
posaconazole, and voriconazole; and 0.008e8 ug/mL for
anidulafungin, caspofungin, and micafungin. The MIC of
amphotericin B was defined as the lowest drug concentra-
tion to prevent any discernible growth.23,24 MICs of azoles
and echinocandins were defined as the lowest drug con-
centration to produce a prominent decrease in turbidity
(score of 2), which translated to an approximately 50%
reduction in growth relative to the drug-free growth con-
trol.24 RPMI-1640 buffered to pH 7.0 with 0.165 M mor-
pholinepropanesulfonic acid was applied.24 The control
strains Candida albicans ATCC 90028 and Candida krusei
ATCC 6258 were used in all tests.23,24
Statistical analysis
Descriptive statistics such as means, standard deviation,
frequency, and percentage were conducted. Chi-square
test, Fisher’s exact test, unpaired t test, and analysis of
variance were used to compare data among groups when
appropriate. Logistic regression with forward selection was
Table 2 Analysis of outcome of 109 evaluable cases of candidemia with multiple logistic regression
Candidemia treatment Multiple logistic regression
Cured Failure p Adjusted odds ratio p
Group <0.001a
Group A 44 (62.9) 26 (37.1) Reference
Group B, Group C 4 (10.3) 35 (89.7) 11.0 (3.4e36.0) <0.001
APACHE III <0.001a 0.0099
<40 25 (69.4) 11 (30.6) Reference
40e60 13 (50.0) 13 (50.0) 1.6 (0.5e5.1) 0.4531
>60 10 (21.3) 37 (78.7) 5.2 (1.7e15.4) 0.0032
a Chi-square test.
Data are presented as n (%).
APACHE Z Acute Physiology and Chronic Health Evaluation.
248 S.-C. Lee et al.used to determine the important factors for prognosis with
variables such as age, underlying diseases, APACHE III
score, persistent candidemia, and antimicrobial therapy.
Odds ratios (ORs) with 95% confidence interval (CI) were
determined to indicate the risk of failure. A p value < 0.05
was considered statistically significant.Results
A total of 109 cases of candidemia were included in our
analysis. Of these, 70 cases were treated with echino-
candins, azoles, or amphotericin B for 7 days and the
other 39 cases were treated inadequately. The clinical cure
rates of cases treated adequately and inadequately due to
late or postmortem diagnosis were 44/70 (62.9%) and 4/39
(10.2%) respectively, and with significant difference (Table
1). According to logistic regression, adequate antifungal
therapy and the APACHE III score were both independent
significant factors for the clinical outcome (Table 2).
Because one case of candidemia was treated with ampho-
tericin B only, there were 69 evaluable cases of candidemia
adequately treated with echinocandins or azoles. Clinical
cure rates of anidulafungin, caspofungin, micafungin, and
fluconazole were 18/30 (60.0%), 8/9 (88.9%), 5/7 (71.4%),
and 9/18 (50%), respectively (Table 3). Regarding the
APACHE III score, there was no significant difference among
these four treatment groups. However, the difference in
APACHE III score between treatment cure and failure cases
was significant, indicating that patients with high APACHE
III score were too sick to complete the course of treatment
(Table 3). When echinocandins were evaluated together
and compared with fluconazole group, the clinical cure rate
was higher in the echinocandins group (72.7% in echino-
candins group; 50.0% in fluconazole group; Table 4) without
significant difference (Table 4). Regarding the mortality
rate due to candidemia, significant differences were found
between cases with and without early antifungal therapy
and between those with and without adequate antifungal
therapy (Table 5). The outcome of another nine cases of
candidemia was in the treatment failure group who ulti-
mately survived and was not included in the study of risk
factors for mortality (Table 5). However, there was no
significant difference in the mortality rate due tocandidemia between those cases with and without persis-
tent candidemia (Table 5). The in vitro activities of azoles
to Candida isolates of candidemia are shown in Table 6.
Candida glabrata and C. krusei were totally resistant to
fluconazole whereas the other azoles such as itraconazole,
posaconazole, and voriconazole showed lower MIC impli-
cated clinical efficient (Table 6). The MICs of anidulafungin,
caspofungin, and micafungin in C. parapsilosis were higher
than that in other Candida spp. (Table 6). The MIC50/MIC90
of anidulafungin, caspofungin, and micafungin for all
Candida spp. were 0.03/1 mg/mL, 0.06/0.5 mg/mL, and
0.008/1 mg/mL, respectively (Table 6).Discussion
According to a prior report, the clinical correlation of the
reference antifungal susceptibility test results was high in
hematogenous and deep-seated Candida infections when
co-existing bacterial infections were treated with appro-
priate antibiotics, superinfection or reinfection as defined
in the exclusion criteria was excluded, inadequate anti-
fungal therapy was avoided, and essential surgical inter-
vention was performed.19 Because the MICs of
echinocandins to all Candida spp. were still within the
susceptible range, factors other than susceptibility result
should be present to explain those candidemia cases
treated unsuccessfully with echinocandins. In the present
study, a significant difference was seen between the
APACHE III score of the treatment cure group and the
treatment failure group (Tables 1e4). Therefore, APACHE
III score on the culture-positive day affects the clinical
outcome. The impact on the outcome was significant when
the APACHE III score was above 60 (Table 2). Because the
APACHE III score was lower in the candidemia cases treated
successfully with echinocandins or azoles, we clarified the
relationship between adequate antifungal therapy and
APACHE III score with multiple logistic regression and thus
found that adequate antifungal therapy and APACHE III
score are the independent factors affecting the clinical
outcome (Table 2). We also found a significant difference in
the treatment failure rate between cases treated
adequately (7 days) with antifungal agents and treated
inadequately with antifungal agents (<7 days) or not
Table 3 Outcome of 69 evaluable cases of candidemia adequately treated with echinocandins or azolesa
Casp (n Z 9) Anid (n Z 30) Mica (n Z 7) Flu (n Z 18) Candins or
azoles
combination
(n Z 5)
p APACHE III score,
mean (range)
p
Total treatment
duration (d)
19.9  6.6
(12e28)
19.4  10.6
(7e51)
21.1  9.3
(9e37)
14.8  6.5
(7e30)
23.4  9.5
(10e34)
0.2521b
Candins treatment
duration (d),
mean (range)
13.8  4.2
(7e22)
12.9  7.4
(4e34)
14.86  8.4
(2e28)
d d 0.7919b
Candidemia
treatment
Cured 8 (88.9) 18 (60.0) 5 (71.4) 9 (50.0) 4 (80.0) 0.3358c 42.3  20.7
(4e84)
0.0038d
Failure 1 (11.1) 12 (40.0) 2 (28.6) 9 (50.0) 1 (20.0) 59.5  26.6
(13e112)
Expired due to
candidemia
1 (11.1) 8 (26.7) 2 (28.6) 7 (38.9) 1 (20.0) 0.7044c
APACHE III score 50.9  23.5
(26e84)
47.3  26.4
(4e112)
48.0  25.1
(20e81)
50.6  21.2
(23e90)
44.4  30.4
(10e88)
0.9805a
MIC mg/mL Fluc:1.028
(0.25e4)
Casp:0.29
(0.03e1)
Fluc:3.58
(0.25e16)
Anid:0.258
(0.015e1)
Fluc:0.367
(0.12e1)
Mica:0.047
(0.015e0.25)
3.451
(0.12e32)
Fluc:1.1
(0.5e2)
Anid:0.072
(0.03e0.12)
Casp:0.61
(0.06e0.25)
Mica:0.02
(0.008e0.03
Vori:0.06
(0.015e0.12
a Five cases were unresponsive to 5e18 days of fluconazole initially, of which three cases had persistent candidemia; 19 cases we nresponsive to 1e20 days of fluconazole initially, of
which five cases had persistent candidemia; two cases were unresponsive to 20e24 days of fluconazole initially, of which one ca had persistent candidemia. Candins or azoles com-
bination: Fluc þ Anid þ Casp (1); Fluc þ Anid þ Mica (1); Fluc þ Casp þ Vori (1); Anid þ Mica (1); Cas þ Mica (1). Of 109 cases candidemia, only 69 cases adequately treated with
echinocandins or fluconazole could be evaluated for response to these antifungal agents. One case of candidemia was treated w amphotericin B only.
b Analysis of variance.
c Fisher’s exact test.
d Independent t test.
Data are presented as n (%), mean  SD (range), or mean (range).
AnidZ anidulafungin; APACHEZ Acute Physiology and Chronic Health Evaluation; CaspZ caspofungin; FlucZ fluconazole; MicaZ icafungin; MICZ minimal inhibitory concentration;
SD Z standard deviation.
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Table 4 Outcome of 40 evaluable cases of candidemia adequately treated with only echinocandins or fluconazole
Candins (n Z 22)a Fluconazole (n Z 18) p APACHE III
score,
mean (range)
p
Candidemia cured 16 (72.7) 9 (50.0) 0.1396b 42.5  21.8 (12e84) 0.0460d
Candidemia treatment failure 6 (27.3) 9 (50.0) 57.9  24.5 (13e90)
Expired due to candidemia 4 (18.2) 7 (38.9) 0.1734c
Treatment duration, d 15.5  0.8 (7e34) 14.8  6.5 (7e30) 0.7739d
APACHE III score 46.3  26.0 (12e88) 50.6  21.2 (23e90) 0.5765d
a Twenty-two candidemia cases treated with echinocandins only included caspofungin (n Z 4), anidulafungin (n Z 11), micafungin
(n Z 5), anidulafungin followed by micafungin (n Z 1) and caspofungin followed by micafungin (n Z 1).
b Chi-square test.
c Fisher’s exact test.
d Independent t test.
Data are presented as n (%) or mean (range).
APACHE Z Acute Physiology and Chronic Health Evaluation.
250 S.-C. Lee et al.treated with antifungal agents (Table 1). In those cases not
treated with antifungal agents (Group C), the result of
blood culture was known postmortem. In those cases
treated inadequately with antifungal agents for <7 days
(Group B), the result of blood culture was known late in the
course of candidemia. Therefore, early diagnosis of candi-
demia and early initiation of effective antifungal therapy
are both very important in the treatment of candidemia in
order to provide adequate antifungal therapy prior to when
the patients become very critical. In Group B of the 17
candidemia cases that were inadequately treated (<7
days), one case survived, 14 cases expired due to candi-
demia, and the remaining two cases expired due to non-
candidemia causes. In Group C of the 22 candidemia cases
without any antifungal therapy, three cases survived, 18
cases expired due to candidemia and the remaining case
expired due to noncandidemia cause. Survival for these
four candidemia cases without adequate or any antifungal
therapy might be resulted from the transient nature of
candidemia and the better physiological immune status in
them. The APACHE III score of these four survival patients
was 28.5  19.8, significantly lower than that of the failure
cases in Groups B and C (Table 1).
In cases treated with fluconazole, the MICs of flucona-
zole had a wide range, some within the susceptible ranges
(C. albicans, Candida parapsilosis, Candida tropicalis,
Table 6) and the others outside the susceptible ranges (C.
glabrata, C. krusei, Table 6). The mean was 3.45 mg/mL and
the range was 0.12e32 mg/mL. However, in cases treated
with echinocandions, the MICs of anidulafungin, caspo-
fungin, and micafungin were very low, all within the sus-
ceptible ranges. Such difference of susceptibility to
Candida spp. between echinocandins and fluconazole may
explain the higher cure rate of echinocandins (72.7%) and
the lower cure rate of fluconazole (50%) for candidemia
(Table 4). Thus, fluconazole was inferior to echinocandins
in the treatment of candidemia clinically. The in vitro ac-
tivity of fluconazole was also inferior to echinocandins
except for C. parapsilosis, in which the MICs of echino-
candins and fluconazole were similar (Table 6). We had
analyzed the relationship between MICs of fluconazole and
the outcome of candidemia cases caused by C. parapsilosis.Among the 26 cases of candidemia due to C. parapsilosis,
nine cases with APACHE III score 41.11  25.33 (range,
4e81) were treated with fluconazole adequately of which
six cases were cured and three cases expired within 30 days
of the culture-positive date; nine cases with APACHE III
score 41.22  28.89 (range, 12e84) were treated
adequately with echinocandins of which eight cases were
cured and one case expired within 30 days of the culture-
positive date. One case of candidemia due to C. para-
psilosis with APACHE III score 19 was cured with ampho-
tericin B but died of other causes 3 months later. The
remaining seven cases of candidemia due to C. parapsilosis
were not treated with any antifungal agent due to late or
postmortem diagnosis of which four cases with APACHE III
score 30.00  20.70 (range, 0e46) survived and three cases
with APACHE III score 56.67  24.42 (range, 37e84) expired
within 10 days of culture-positive date. These data indi-
cated that although fluconazole is not inferior to echino-
candins in MIC susceptibility test of C. parapsilosis,
echinocandins is not inferior to fluconazole in treating
candidemia due to C. parapsilosis clinically. In candidemia
cases that are frequently critical and severe, echinocandins
are preferred rather than fluconazole unless the MICs of
fluconazole can be known immediately and are found
within the susceptible range.
Although the number of candidemia cases was small in
some groups of treatment with various antifungal agents,
the difference in treatment outcome with different anti-
fungal agents were revealed (Table 3). However, significant
difference in the clinical cure rates among these three
echinocandins still might not be achieved even if we
include more candidemia cases by extending the study
period. Alternatively, a comparative in vitro fungicidal
activity study of these three echinocandins may disclose
which echinocandin has the highest clinical cure rate.
Although the MIC of micafungin was the lowest among the
three echinocandins (Table 6), the clinical cure rate of
caspofungin was higher than that of anidulafungin and
micafungin in this study although this was not statistically
significant (Table 3). According to Table 3, the APACHE III
scores of candidemia cases using caspofungin, anidula-
fungin, micafungin, and fluconazole were not significant
Table 5 Evaluation of risk factors for mortality due to candidemia in 100 evaluable cases of candidemiaa
Cured of candidemia
(n Z 48)
Expired due to
candidemia (n Z 52)
p
Sex M 25 (52.1)b 29 (55.8)b 0.7118d
F 23 (47.9)b 23 (44.2)b
Age, y, mean (range) 70.4  12.2 (43e91) 70.8  19.1 (10e103) 0.9021e
Underlying diseases
Chronic obstructive pulmonary
diseases
Y 5 (10.4)b 6 (11.5)c 0.8578d
N 43 (89.6)b 46 (88.5)c
Congestive heart failure Y 3 (6.3)b 4 (7.7)c 0.7776d
N 45 (93.8)b 48 (92.3)c
End-stage renal diseases
under regular hemodialysis
Y 7 (14.6)b 10 (19.2)c 0.5365d
N 41 (85.4)b 42 (80.8)c
Chronic renal failure without
hemodialysis
Y 1 (2.1)b 2 (3.9)c 0.6057d
N 47 (97.9)b 50 (96.2)c
Chronic cerebral vascular
diseases
Y 9 (18.8)b 5 (9.6)b 0.1884d
N 39 (81.3)b 47 (90.3)b
Liver cirrhosis Y 2 (4.2)b 8 (15.4)b 0.0945f
N 46 (95.8)b 44 (84.6)b
Malignancy Y 21 (43.8)b 16 (30.8)b 0.1792d
N 27 (56.3)b 36 (69.2)b
Rheumatic diseases Y 7 (14.6)b 5 (9.6)b 0.4450d
N 41 (85.4)b 47 (90.4)b
Neutropenia Y 4 (8.3)b 4 (7.7)b 0.9060d
N 44 (91.7)b 48 (92.3)b
Others Y 37 (77.1)b 39 (75.0)b 0.8075d
N 11 (22.9)b 13 (25.0)b
APACHE III, mean (range) 41.1  20.8 (0e84) 69.3  23.9 (19e128) <0.0001e
Persistent candidemia > 24 h
(n Z 24)
Y 13 (27.1)b 11 (21.2)b 0.4879d
N 35 (72.9)b 41 (78.9)b
Persistent candidemia > 72 h
(n Z 20)
Y 10 (20.8)b 10 (19.2)b 0.8414d
N 38 (79.2)b 42 (80.8)b
Persistent candidemia > 24 h
with fluconazole
2 (40.0)c 3 (60.0)c 0.6299f
Persistent candidemia > 24 h
with candins
11 (57.9)c 8 (42.1)c
Persisitent candidemia,
d, mean (range)
6.93  6.3 (1e25) 8.4  8.6 (1e33) 0.6160e
Early AT (n Z 40) Y 25 (52.1)b 15 (28.9)b 0.0178d
N 23 (47.9)b 37 (71.2)b
Adequate AT (n Z 64) Y 44 (91.7)b 20 (38.5)b <0.0001d
N 4 (8.3)b 32 (61.5)b
Adequate AT with fluconazole
(n Z 16)
9 (56.3)c 7 (43.8)c 0.2092f
Adequate AT with candins
(n Z 20)
16 (80.0)c 4 (20.0)c
Adequate AT with
candins þ azole (n Z 27)
19 (70.4)c 8 (29.6)c
Adequate AT with
amphotericin B
0 1 (100.0)c
a Outcome of another nine cases of candidemia was in the treatment failure group who ultimately survived.
b Column percentage.
c Row percentage.
d Chi-square test.
e Independent t test.
f Fisher’s exact test.
Data are presented as n (%).
AT Z antimicrobial therapy.
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252 S.-C. Lee et al.different. Therefore, under the same APACHE III score
level, caspofungin still had a better outcome though the
difference of outcome among cases treated with these
three drugs were not significant. Because there was no
significant difference in the APACHE III score among the
three groups of candidemia cases treated with anidula-
fungin, caspofungin, and micafungin respectively, there
should be other factors such as fungicidal activity that were
responsible for the difference in the cure rates among
these three echinocandins.
Regarding risk factors of mortality due to candidemia,
only APACHE III score, early antifungal therapy, and
adequate antifungal therapy are significant statistically in
the present study (Table 5) and are consistent with prior
reports.25e27 However, persistent candidemia is not a risk
factor of mortality in candidemia treated with echocandins
or fluconazole in this study, which differs from prior re-
ports.28 The outcome of another nine cases of candidemia
in the treatment failure group who ultimately survived was
not included in the study of risk factors for mortality. This
finding indicates that the antifungal agents used in these
nine cases of candidemia are not effective enough to cure
the candidemia with a persistence of fever or sign of active
infection, although they clinically improved and the
repeated blood culture became negative. Subsequently,
the immune status of the patients improved and candide-
mia became resolved completely.
We conclude that: (1) adequate antifungal therapy and
APACHE III score are independent factors affecting the
clinical outcome; (2) the clinical cure rate of the echino-
candins group was higher than that of the fluconazole group
without significant difference; (3) although caspofungin has
the best clinical cure rate in this study, there is no signifi-
cant difference between the clinical cure rate among these
three echinocandins; and (4) all Candida spp. were sus-
ceptible in vitro to these three echinocandins. Further
clinical and in vitro studies are needed to clarify the dif-
ference in the clinical cure rates among anidulafungin,
caspofungin, and micafungin.
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